Year Founded
2015
Ownership
Private
Employees
~100
Therapeutic Areas
Oncology
Stage
Commercial
Modalities
Molecular diagnostics

Strata Oncology General Information

Developed proprietary biomarker algorithms including Immunotherapy Response Score (IRS) and ADC Treatment Response Scores for predicting treatment benefit. Recently demonstrated utility of IRS in predicting pembrolizumab benefit in NSCLC patients.

Contact Information

Website
Primary Industry
Diagnostics
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Strata Oncology's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Strata Oncology Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Strata Oncology's complete valuation and funding history, request access »

Strata Oncology Investors

Notable investors not specifically named in search results but referenced as present on website/investors page.
Investor Type: Venture Capital
Holding: Minority